Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results

✍ Scribed by Samuel G. Taylor IV; Anantha K. Murthy; Katherine L. Griem; Diane C. Recine; Krystyna Kiel; Carol Blendowski; Patricia Bull Hurst; John T. Showel; James C. Hutchinson Jr; Ruth S. Campanella; Shande Chen; David D. Caldarelli

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 60 KB
• Volume: 19
• Category: Article
• ISSN: 1043-3074
• DOI: 10.1002/(sici)1097-0347(199712)19:8<684::aid-hed6>3.0.co;2-1

✦ Synopsis

Background. The purpose of this study was to analyze long-term follow-up of a single institution's experience with a regimen of concomitant cisplatin/fluorouracil (5-FU) infusion and radiation given every other week. This analysis was stimulated by results of a randomized trial showing superiority for this regimen over induction cisplatin/5-FU chemotherapy followed by radiotherapy, especially in regional disease control.

Methods. All patients with stage III/IV disease who were referred by surgeons for nonoperative therapy and had a follow-up of at least 2 years were included. Concomitant chemoradiotherapy was administered days 1-5 of a 2-week treatment cycle, for a total of 7 cycles, with cisplatin 60 mg/m 2 day 1, 5-FU 800 mg/m 2 given over 24 hours days 1-5, and radiation 2 Gy days 1-5.